Alkermes PLC(ALKS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALKS Alkermes PLC

Post-Mkt 12-18 17:10:42 EST

27.81

-0.23

-0.82%

盘后27.81

+0.000.00%

16:20 EST

High28.50	Low27.69	Vol1.39M
Open28.23	D1 Closing28.04	Amplitude2.89%
Mkt Cap4.59B	Tradable Cap4.52B	Total Shares165.12M
T/O38.93M	T/O Rate0.86%	Tradable Shares162.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALKS","market":"US","secType":"STK","nameCN":"Alkermes PLC","latestPrice":27.81,"timestamp":1766091600000,"preClose":28.04,"halted":0,"volume":1393918,"hourTrading":{"tag":"盘后","latestPrice":27.81,"preClose":27.81,"latestTime":"16:20 EST","volume":53822,"amount":1496789.712356,"timestamp":1766092800396},"delay":0,"floatShares":162415981,"shares":165117509,"eps":2.017266,"marketStatus":"Post-Mkt","change":-0.23,"latestTime":"12-18 17:10:42 EST","open":28.23,"high":28.5,"low":27.69,"amount":38931263.806358,"amplitude":0.028887,"askPrice":28,"askSize":10,"bidPrice":27.69,"bidSize":15,"shortable":3,"etf":0,"ttmEps":2.017266,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766106000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":28.04,"preHourTrading":{"tag":"盘前","latestPrice":28.2,"preClose":28.04,"latestTime":"09:29 EST","volume":103,"amount":2904.1201229999997,"timestamp":1766068199999},"postHourTrading":{"tag":"盘后","latestPrice":27.81,"preClose":27.81,"latestTime":"16:20 EST","volume":53822,"amount":1496789.712356,"timestamp":1766092800396},"volumeRatio":0.791453,"impliedVol":0.6597,"impliedVolPercentile":0.916},"requestUrl":"/m/hq/s/ALKS/tweets","defaultTab":"tweets","newsList":[{"id":"2590248523","title":"HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes","url":"https://stock-news.laohu8.com/highlight/detail?id=2590248523","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590248523?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:16","pubTimestamp":1765315000,"startTime":"0","endTime":"0","summary":"Avadel Pharmaceuticals plc disclosed that the waiting period for regulatory review has expired regarding the planned acquisition of Avadel by Alkermes plc. This development marks the satisfaction of a key condition for the closing of the transaction. Completion of the acquisition remains subject to additional customary conditions, including approval by Avadel shareholders and final approval by the Irish High Court.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL3mMz2p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVDL","ALKS","BK4139","BK4007"],"gpt_icon":0},{"id":"2589537810","title":"Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589537810","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589537810?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:22","pubTimestamp":1764969726,"startTime":"0","endTime":"0","summary":"Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported a disposal of common shares of Alkermes plc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL86Zkg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"gpt_icon":0},{"id":"2588706164","title":"Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588706164","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588706164?lang=en_us&edition=fundamental","pubTime":"2025-12-02 06:42","pubTimestamp":1764628927,"startTime":"0","endTime":"0","summary":"Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reported a disposal of common shares of Alkermes plc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL7lN6rY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D and Chief Medical Officer Craig C. Hopkinson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"gpt_icon":0},{"id":"2588708036","title":"Avadel Pharmaceuticals Plc - Scheme Meeting and Egm Scheduled for January 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588708036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588708036?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:06","pubTimestamp":1764623185,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70R7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVDL","BK4139","ALKS"],"gpt_icon":0},{"id":"2588488718","title":"A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2588488718","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588488718?lang=en_us&edition=fundamental","pubTime":"2025-12-01 01:11","pubTimestamp":1764522684,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) gained attention after its third quarter earnings surpassed consensus expectations. Sales growth from Vivitrol, Aristada, and Lybalvi contributed to this performance. The company also raised its outlook for 2025 revenues.\nSee our latest analysis for Alkermes.\nAlkermes’ upbeat third quarter results and guidance boost have kept investor attention on its growth potential, even as the company prepares to acquire Avadel Pharmaceuticals early next year. The momentum from a 16%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/a-look-at-alkermes-alks-valuation-following-q3-earnings-beat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALKS"],"gpt_icon":0},{"id":"2586370248","title":"BUZZ-H Lundbeck steps down from takeover for Avadel, shares rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586370248","media":"Reuters","labels":["shareholding","corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586370248?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:29","pubTimestamp":1764232155,"startTime":"0","endTime":"0","summary":"BUZZ-H Lundbeck steps down from takeover for Avadel, shares rise 3%** Shares in H Lundbeck HLUNa.CO rise 3.3% after the Danish pharmaceutical company said it would not increase a purchase price in a takeover offer for Avadel Pharmaceuticals AVDL.O ** Lundbeck added that its strategic rationale for engaging in the sleep disorders space stays \"fully intact\"** The Danish company made an unsolicited bid for Avadel on November 14, offering up to $23 per share** Drugmaker Alkermes ALKS.O, who also made a bid for Avadel, sweetened its offer to $2.37 billion, which Avadel's board recommended to its shareholders on November 19** H Lundbeck shares were up 1.3% at 08:27 GMT  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nL8N3X30AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ALKS","AVDL"],"gpt_icon":0},{"id":"2586940603","title":"Alkermes plc to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586940603","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586940603?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:00","pubTimestamp":1764104416,"startTime":"0","endTime":"0","summary":"Alkermes plc will participate in two upcoming investor conferences. The company will attend the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 2:10 p.m. ET, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 12:00 p.m. ET. Live webcasts of both events will be available on the Alkermes website under the Investors tab and will be archived for 14 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL38rb0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","EVR","PIPR","BK4139","ALKS"],"gpt_icon":0},{"id":"2585450152","title":"Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2585450152","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585450152?lang=en_us&edition=fundamental","pubTime":"2025-11-20 23:23","pubTimestamp":1763652181,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) just reported encouraging topline results from its Vibrance-2 phase 2 trial testing alixorexton in narcolepsy type 2. The study hit key efficacy goals and safety markers, which has sparked new attention for the company’s neurology portfolio.\nSee our latest analysis for Alkermes.\nThe recent buzz from Alkermes' positive Vibrance-2 results comes on the heels of active participation in major healthcare conferences, all while the share price remains steady at $28.69. Despite some...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/alkermes-alks-evaluating-valuation-after-promising-vibrance","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alks/alkermes/news/alkermes-alks-evaluating-valuation-after-promising-vibrance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALKS"],"gpt_icon":0},{"id":"2584630923","title":"Deals of the day-Mergers and acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2584630923","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584630923?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:00","pubTimestamp":1763568003,"startTime":"0","endTime":"0","summary":"Deals of the day-Mergers and acquisitionsAdds: Adobe, China International Capital Corp,  Alkermes Updates:September 19 (Reuters) - The following bids, mergers, acquisitions and disposals were reported","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV0U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHEL.UK","LU0654597011.USD","LU0433182093.SGD","AVDL","LU1580142542.USD","BK4139","LU2458330169.SGD","LU0708994859.HKD","LU0128525689.USD","LU0889566641.SGD","LU1084165304.USD","LU0719512351.SGD","LU1098665638.USD","BK4539","IE00B19Z9505.USD","LU0964806797.USD","LU2089283258.USD","LU0048584097.USD","601995","LU0511384066.AUD","LU1934455277.USD","BK1156","LU0266512127.USD","601059","PSKY","LU0368265418.SGD","LU0861579265.USD","SEMR","LU0006306889.USD","LU0068578508.USD","BK4125","LU1267930573.SGD","BK0009","ALKS","LU1366333091.USD","LU0965508806.USD","601198","LU0612318971.USD","LU0082616367.USD","ITH.UK","LU1720051108.HKD","IE00BYQQ9H92.USD","01359","LU1119994496.HKD","LU0211328371.USD","LU1242518857.USD","BK5159","IE00BFXG0V08.USD","WBD"],"gpt_icon":1},{"id":"2584050942","title":"BRIEF-H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2584050942","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584050942?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:23","pubTimestamp":1763562212,"startTime":"0","endTime":"0","summary":"BRIEF-H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our OptionsNov 19  - Alkermes Plc ALKS.O:H LUNDBECK A/S:  NOTED THAT OUR OFFER FOR ACQUIRING AVADEL NO LONGER IS CONSIDERED SUPERIOR BY THEIR BOARD, WE ARE CURRENTLY CONSIDERING OUR OPTIONSSource text: [ID:]Further company coverage: ALKS.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS","BK4007","AVDL"],"gpt_icon":0},{"id":"2584941809","title":"H Lundbeck a/S:  Noted That Our Offer for Acquiring Avadel No Longer Is Considered Superior by Their Board, We Are Currently Considering Our Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2584941809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584941809?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:08","pubTimestamp":1763557702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","BK4007","ALKS","BK4139"],"gpt_icon":0},{"id":"2584910084","title":"Alkermes Raises Offer to Acquire Avadel Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910084","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910084?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:01","pubTimestamp":1763550068,"startTime":"0","endTime":"0","summary":"Alkermes plc has increased its offer to acquire Avadel Pharmaceuticals plc, matching the $21.00 per share cash consideration proposed in a competing bid from Lundbeck. According to Alkermes, the revised terms include a contingent value right  that is considered superior to that offered in the Lundbeck proposal, which Avadel's board determined was unlikely to be achieved. Following a review with its advisors, Avadel's board concluded that the Alkermes offer is now more favorable than the Lundbeck proposal. Financial and legal advisors for both companies are involved in advancing the transaction, with J.P. Morgan providing fully committed financing to Alkermes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the ori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL7wZ42K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","BK4007","BK4139","AVDL"],"gpt_icon":0},{"id":"2584948867","title":"Alkermes: Proposed Deal Consideration Consists of $21.00 in Cash and One Non-Transferable CVR for Potential Additional Cash Payment of $1.50/Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2584948867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584948867?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA67XLCB:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALKS","BK4139","AVDL"],"gpt_icon":0},{"id":"2584910799","title":"Alkermes Plc - Deal Valued up to $22.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910799?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA67XLCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVDL","BK4139","ALKS"],"gpt_icon":0},{"id":"2584910743","title":"Alkermes Plc Announces Increased Offer to Acquire Avadel Pharmaceuticals Plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910743?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA67XLCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVDL","ALKS","BK4139"],"gpt_icon":0},{"id":"2584910060","title":"Alkermes Plc - Avadel Board Rejects Lundbeck Proposal as Superior","url":"https://stock-news.laohu8.com/highlight/detail?id=2584910060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584910060?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA67XLCB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVDL","ALKS","BK4007","BK4139"],"gpt_icon":0},{"id":"2584891001","title":"Alkermes Plc: Avadel Board Determined Terms of CVR in Alkermes' Increased Offer Are Superior to Terms of CVR Included in Lundbeck Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2584891001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584891001?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA67XLCB:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ALKS","AVDL"],"gpt_icon":0},{"id":"2584792910","title":"Alkermes Plc - Revised Deal Approved by Alkermes and Avadel Boards","url":"https://stock-news.laohu8.com/highlight/detail?id=2584792910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584792910?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:00","pubTimestamp":1763550000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA67XLCB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","AVDL","BK4007","BK4139"],"gpt_icon":0},{"id":"2584264756","title":"Alkermes Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2584264756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584264756?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:35","pubTimestamp":1763386500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 08:35 ET (13:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALKS"],"gpt_icon":0},{"id":"2584628678","title":"Alkermes Plc : Truist Securities Raises Target Price to $55 From $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2584628678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584628678?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:16","pubTimestamp":1763381808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT157:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alkermes.com","stockEarnings":[{"period":"1week","weight":-0.0203},{"period":"1month","weight":-0.044},{"period":"3month","weight":-0.0179},{"period":"6month","weight":-0.0361},{"period":"1year","weight":-0.0881},{"period":"ytd","weight":-0.025}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.764706,"avgChangeRate":0.087386},{"month":2,"riseRate":0.441176,"avgChangeRate":0.05532},{"month":3,"riseRate":0.411765,"avgChangeRate":-0.046005},{"month":4,"riseRate":0.441176,"avgChangeRate":-0.028743},{"month":5,"riseRate":0.558824,"avgChangeRate":0.051838},{"month":6,"riseRate":0.470588,"avgChangeRate":0.00341},{"month":7,"riseRate":0.529412,"avgChangeRate":0.023052},{"month":8,"riseRate":0.485714,"avgChangeRate":0.043862},{"month":9,"riseRate":0.428571,"avgChangeRate":0.001956},{"month":10,"riseRate":0.514286,"avgChangeRate":0.03285},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.011873},{"month":12,"riseRate":0.685714,"avgChangeRate":0.054508}],"exchange":"NASDAQ","name":"Alkermes PLC","nameEN":"Alkermes PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alkermes PLC(ALKS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alkermes PLC(ALKS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alkermes PLC,ALKS,Alkermes PLC股票,Alkermes PLC股票老虎,Alkermes PLC股票老虎国际,Alkermes PLC行情,Alkermes PLC股票行情,Alkermes PLC股价,Alkermes PLC股市,Alkermes PLC股票价格,Alkermes PLC股票交易,Alkermes PLC股票购买,Alkermes PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alkermes PLC(ALKS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alkermes PLC(ALKS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction